tetano
Editor, Senior Moderator
Biomed Pharmacother
. 2022 Jan 4;147:112614.
doi: 10.1016/j.biopha.2022.112614. Online ahead of print.
Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells
Sepideh Zununi Vahed[SUP] 1 [/SUP], Seyed Mahdi Hosseiniyan Khatibi[SUP] 2 [/SUP], Elham Ahmadian[SUP] 1 [/SUP], Mohammadreza Ardalan[SUP] 3 [/SUP]
Affiliations
Abstract
Post-Covid pulmonary fibrosis is evident following severe COVID-19. There is an urgent need to identify the cellular and pathophysiological characteristics of chronic lung squeals of Covid-19 for the development of future preventive and/or therapeutic interventions. Tissue-resident memory T (T[SUB]RM[/SUB]) cells can mediate local immune protection against infections and cancer. Less beneficially, lung T[SUB]RM[/SUB] cells cause chronic airway inflammation and fibrosis by stimulating pathologic inflammation. The effects of Janus kinase (JAK), an inducer pathway of cytokine storm, inhibition on acute Covid-19 cases have been previously evaluated. Here, we propose that Tofacitinib by targeting the CD8[SUP]+[/SUP] T[SUB]RM[/SUB] cells could be a potential candidate for the treatment of chronic lung diseases induced by acute SARS-CoV-2 infection.
Keywords: Coronavirus; JAK inhibitors; Pulmonary fibrosis; SARS-CoV-2; Severe lung injury.
. 2022 Jan 4;147:112614.
doi: 10.1016/j.biopha.2022.112614. Online ahead of print.
Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells
Sepideh Zununi Vahed[SUP] 1 [/SUP], Seyed Mahdi Hosseiniyan Khatibi[SUP] 2 [/SUP], Elham Ahmadian[SUP] 1 [/SUP], Mohammadreza Ardalan[SUP] 3 [/SUP]
Affiliations
- PMID: 34995938
- PMCID: PMC8723825
- DOI: 10.1016/j.biopha.2022.112614
Abstract
Post-Covid pulmonary fibrosis is evident following severe COVID-19. There is an urgent need to identify the cellular and pathophysiological characteristics of chronic lung squeals of Covid-19 for the development of future preventive and/or therapeutic interventions. Tissue-resident memory T (T[SUB]RM[/SUB]) cells can mediate local immune protection against infections and cancer. Less beneficially, lung T[SUB]RM[/SUB] cells cause chronic airway inflammation and fibrosis by stimulating pathologic inflammation. The effects of Janus kinase (JAK), an inducer pathway of cytokine storm, inhibition on acute Covid-19 cases have been previously evaluated. Here, we propose that Tofacitinib by targeting the CD8[SUP]+[/SUP] T[SUB]RM[/SUB] cells could be a potential candidate for the treatment of chronic lung diseases induced by acute SARS-CoV-2 infection.
Keywords: Coronavirus; JAK inhibitors; Pulmonary fibrosis; SARS-CoV-2; Severe lung injury.